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Abstract
Rationale Attentional processing deficits are a core feature of schizophrenia, likely contributing to the persistent functional and
occupational disability observed in patients with schizophrenia. The pathophysiology of schizophrenia is hypothesized to involve
dysregulation of NMDA receptor-mediated glutamate transmission, contributing to disruptions in normal dopamine transmis-
sion. Preclinical investigations often use NMDA receptor antagonists, such as phencyclidine (PCP), to induce cognitive disrup-
tions relevant to schizophrenia. We sought to test the ability of partial dopamine D2/D3 agonists, cariprazine and aripiprazole, to
attenuate PCP-induced deficits in attentional performance.
Objectives The objective of this study is to determine whether systemic administration of cariprazine or aripiprazole attenuated 5-
choice serial reaction time task (5-CSRTT) deficits induced by repeated exposure to PCP.
Methods We utilized a repeated PCP-treatment regimen (2 mg/kg, subcutaneous [s.c.], once daily for 5 days) in rats to induce
deficits in the 5-CSRTT. Rats were pre-treated with cariprazine (0.03, 0.1, or 0.3 mg/kg, oral [p.o.]) or aripiprazole (1, 3, or
10 mg/kg, p.o.) to determine whether they prevented PCP-induced deficits in the 5-CSRTT performance.
Results PCP treatment increased inappropriate responding in the 5-CSRTT, elevating incorrect, premature, and timeout re-
sponses. Cariprazine treatment reduced PCP-induced increases in inappropriate responding. However, at higher doses,
cariprazine produced non-specific response suppression, confounding interpretation of the attenuated PCP-induced deficits.
Aripiprazole treatment also attenuated PCP-induced deficits; however, unlike cariprazine treatment, aripiprazole reduced correct
responding and increased omissions.
Conclusions Cariprazine and aripiprazole both demonstrated potential in attenuating PCP-induced deficits in the 5-CSRTT
performance. While both compounds produced non-specific response suppression, these effects were absent when 0.03 mg/kg
cariprazine was administered.
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Introduction
Schizophrenia is a chronic disorder associated with psychotic
disturbances, negative symptoms, and cognitive dysfunction.
Cognitive deficits are a prominent feature of schizophrenia.
Indeed, cognitive impairments are evident before the onset of
psychotic outbreaks, persist despite therapeutic intervention,
and appear to be a stable feature of the illness. As cognitive
impairments are largely unresponsive to currently available
medications and are thought to significantly contribute to the
functional disability associated with the disorder, the identifica-
tion of novel and efficacious therapeutic strategies is essential.
The National Institute of Mental Health’s Measurement and
Treatment Research to Improve Cognition in Schizophrenia
(MATRICS) initiative identified several cognitive domains that
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are disrupted in patients with schizophrenia, including attention
and vigilance (Kern et al. 2004; Young and Geyer 2015).
Attention is a cognitive process that allows an individual to
detect, select, and process sensory stimuli (Maunsell and
Treue 2006). Impairments in attention have been associated
with schizophrenia since the earliest descriptions of the disor-
der (Kraepelin 1921). Furthermore, attentional processing is
suggested to form an underlying basis of several higher-order
cognitive processes (Riedel et al. 2006), many of which were
also implicated by the MATRICS initiative as being disrupted
in schizophrenia (Kern et al. 2004). Thus, attentional deficits in
schizophrenia may contribute to the spectrum of cognitive dys-
function observed in patients and the associated functional dis-
abilities. Identifying the mechanism(s) that contribute to atten-
tional deficits, and subsequent therapeutic strategies to improve
attentional functioning, may be a key to improving the patients’
quality of life.
N-methyl-D-aspartate (NMDA) glutamate receptor
hypofunction is hypothesized to contribute to the pathophys-
iology of schizophrenia, as NMDA receptor antagonists can
induce schizophrenia-like symptoms in otherwise healthy in-
dividuals that recapitulate aspects of positive, negative, and
cognitive symptomatology (Corlett et al. 2007; Krystal et al.
1994; Pomarol-Clotet et al. 2006). Indeed, it has recently been
demonstrated that patients with schizophrenia may exhibit
alterations in the expression of key functional subunits, poten-
tially leading to endogenous NMDA receptor dysfunction in
schizophrenia (Weickert et al. 2013). In addition to glutamate
transmission, cortical hypofunction and sub-cortical hyper-
function of dopamine transmission are reported in patients
with schizophrenia (Howes et al. 2015). Importantly, dopa-
mine transmission is implicated in attentional performance
(Barnes et al. 2012; Boulougouris and Tsaltas 2008; Carli
and Invernizzi 2014; Granon et al. 2000; Nieoullon 2002),
and augmenting dopamine transmission has been suggested
as a potential target in the development of procognitive ther-
apeutics for the treatment of patients with schizophrenia (Gray
and Roth 2007; Ibrahim and Tamminga 2011). Furthermore,
alterations in glutamate transmission can impact normal dopa-
minergic transmission, suggesting that hypotheses that in-
volve these neurotransmitter systems and schizophrenia path-
ogenesis may not be mutually exclusive. Indeed, NMDA re-
ceptor antagonists have been used in experimental animals to
induce deficits in cognitive processing relevant to schizophre-
nia (Grayson et al. 2015; Jentsch and Roth 1999; Neill et al.
2010; Neill et al. 2014; Pratt et al. 2008). Moreover, NMDA
receptor antagonism produces alterations in dopamine trans-
mission (Adams et al. 2002; Kapur and Seeman 2002). Hence,
the use of experimental animal models that utilize NMDA
receptor antagonists to induce deficits in attentional process-
ing, coupled with dopaminergic manipulations to improve at-
tention, may provide insights into the mechanism(s) that con-
tribute to attention deficits in patients with schizophrenia.
The 5-choice serial reaction time task (5-CSRTT) is a well-
validated and widely used behavioral procedure that tests at-
tentional deficits in experimental rodents (Lustig et al. 2012),
and the neural substrates involved in task performance have
been well described (Chudasama and Robbins 2004; Robbins
2002). Previous investigations revealed that the administration
of NMDA receptor antagonists (i.e., phencyclidine [PCP] or
ketamine) to experimental animals impairs attentional pro-
cessing (Amitai and Markou 2009, 2010; Amitai et al. 2007;
Barnes et al. 2014; Nikiforuk and Popik 2014; Thomson et al.
2011). However, acute administration of PCP disrupts the 5-
CSRTT performance in a generalized manner that is difficult
to interpret as a specific cognitive impairment (Amitai and
Markou 2010; Carli and Invernizzi 2014). Therefore, re-
searchers find it advantageous to use a NMDA antagonist-
treatment regimen that allows testing after a washout period
or after repeated exposure to allow tolerance to the non-
specific disruptions to develop (Barnes et al. 2014; Barnes
et al. 2016; Nikiforuk and Popik 2014; Thomson et al.
2011). For instance, we have previously shown that a repeated
PCP-treatment regimen induces cognitive-specific deficits in
5-CSRTT performance (Amitai and Markou 2009, 2010;
Amitai et al. 2007). Deficits in 5-CSRTT performance were
largely attributed to an increase in incorrect responses, omis-
sions, and premature responses. These findings suggest that
aberrant glutamatergic transmission may contribute to the at-
tentional deficits evident in patients with schizophrenia.
Furthermore, PCP-induced deficits in 5-CSRTT performance
were attenuated by clozapine (Amitai et al. 2007) but not
quetiapine treatment (Amitai and Markou 2009).
Interestingly, clozapine displays a greater receptor occupancy
than quetiapine for striatal dopamine receptors (Tauscher et al.
2004). This occupancy difference may account for the differ-
ing efficacy in ameliorating PCP-induced deficits. Using a
pharmacological strategy that attenuates PCP-induced deficits
in attentional performance by augmenting dopamine transmis-
sion may represent an effective therapeutic strategy for pa-
tients with schizophrenia.
Cariprazine is FDA approved to treat adults with
schizophrenia and manic or mixed episodes associated
with bipolar disorder. Cariprazine is a dopamine D3/D2
receptor partial agonist that preferentially binds to the
dopamine D3 receptor (Kiss et al. 2010). It has shown
procognitive and prosocial effects in rodents, improving
PCP-induced deficits in executive functioning, working
memory, recognition memory, and social interaction
(Neill et al. 2016; Zimnisky et al. 2013). Interestingly,
dopamine D3 receptor expression is most abundant in
mesolimbic regions (Kiss et al. 2010) that may be in-
volved in attentional processing (Feja et al. 2014; St.
Peters et al. 2011). Cariprazine may therefore modulate
5-CSRTT performance and attenuate PCP-induced atten-
tional deficits by altering mesolimbic dopamine D3
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receptor activity. Aripiprazole is an FDA approved com-
pound for the treatment of schizophrenia that has D2 re-
ceptor partial agonist activity and a similar pharmacolog-
ical profile to cariprazine (Kiss et al. 2010). However,
unlike cariprazine, it shows very low occupancy of D3
receptors within its antipsychotic-like effective doses that
occupy D2 receptors to a high extent (≥ 80%) (Gyertyán
et al. 2011). Interestingly, a disruption of the 5-CSRTT
performance induced by the infusion of the NMDA recep-
tor antagonist 3-(R)-2-carboxypiperazin-4-propyl-1-phos-
phonic acid (CPP) into the medial prefrontal cortex was
attenuated by aripiprazole (Carli et al. 2011). Aripiprazole
has also shown efficacy in the treatment of cognitive and
negative symptoms in experimental animal models (Nagai
et al. 2009; Wilson and Koenig 2014). Therefore, the aim
of the present study was to identify whether systemic
administration of cariprazine or aripiprazole attenuated
5-CSRTT deficits induced by repeated exposure to PCP
and to explore eventual differences between these com-
pounds in this model.
Experimental procedures
Animals
MaleWistar rats (weighing approximately 225 g; n = 96) were
purchased fromCharles River Laboratories (Raleigh, NC) and
housed two per cage in a climate-controlled room on a 12 h/
12 h reversed light-dark cycle (lights on at 6:00 p.m.); all
behavioral testing was conducted in the animals’ dark cycle.
No environmental enrichment was provided. Food and water
were available ad libitum until behavioral testing began, dur-
ing which time access to food was restricted. All experiments
were conducted in accordance with the guidelines from the
National Institutes of Health and the Association for the
Assessment and Accreditation of Laboratory Animal Care
and were approved by the University of California, San
Diego Institutional Animal Care and Use Committee.
Drugs
Phencyclidine hydrochloride (PCP) (SigmaAldrich,MO) was
dissolved in 0.9% saline and administered by a subcutaneous
(s.c.) injection of a volume of 2 ml/kg and a concentration of
2 mg/kg. Aripiprazole (Forest Laboratories, NY) was
suspended in 2% Tween 80 in distilled H2O and administered
by oral (p.o.) gavage (1, 3, or 10 mg/kg). Cariprazine HCl
(Forest Laboratories, NY) was also dissolved in 2% Tween
80 and administered p.o. (0.03, 0.1, or 0.3 mg/kg). Drugs were
administered according to the treatment regimen described as
follows by an experimenter blind to all treatment groups
throughout testing.
Behavioral apparatus
Training and testing were conducted in operant condition-
ing boxes (Med Associates, St Albans, VT). Each box
was enclosed in a wooden sound-attenuating chamber
and contained a curved rear wall with nine response ap-
ertures, each containing a photobeam at the entrance of
each aperture to detect nose pokes and a 3-W yellow light
to provide a visual stimulus. Metal inserts blocked four
response apertures, leaving holes 1, 3, 5, 7, and 9 free for
exploration. On the opposite wall, a food magazine con-
nected to a food hopper enabled the delivery of food pel-
lets (45 mg rodent pellet, Test Diet 5TUM, Richmond,
IN), which was signaled by the illumination of a 3-W
bulb in the food magazine. A photobeam detected head
entries into the food magazine. Each box was controlled
by a PC running the MedPC software (Med Associates).
Training
Animals were food restricted to 85% of their free-feeding
body weight, although water access was available ad libitum.
Food restriction continued throughout training and testing.
Training was conducted as previously described (Amitai
et al. 2007). Briefly, training began by habituating animals
to the 5-CSRTT chambers for 20 min for 2 days. This initial
habituation was followed by two 20-min sessions in which a
food pellet was non-contingently delivered every 20 s. During
these initial training sessions, each response aperture was
baited with food pellets to encourage exploration. Response
training began with all response apertures illuminated in a
session lasting 30 min. Response in any aperture delivered a
reward pellet; criteria to move onto the next stage was > 70
completed trials.
Animals were then trained in the 5-CSRTT procedure; one
response aperture was illuminated for each trial. A response in
the illuminated aperture resulted in the delivery of a reward
pellet. A response in any aperture that was not illuminated was
deemed an incorrect response and resulted in a 5-s timeout
period (house light extinguished and no food reward deliv-
ered). Failure to respond (omission), responding during the
inter-trial interval (ITI) before the visual stimulus was present-
ed (premature response), or repeated responses after a correct
response (perseverative response) also resulted in a timeout.
Responses made during the timeout period restarted the 5-s
timeout period and were recorded as a timeout response.
These measures are summarized in Table 1. The stimulus du-
ration was initially 30 s and progressively decreased (20, 10,
5, 2.5, 1.5 s) as individual animals reached the predetermined
criteria (> 70 trials completed, > 70% accuracy, and < 20%
omissions) until animals reached the target stimulus duration
of 1 s. Each session lasted 30 min or when 100 trials had been
completed, whichever occurred first.
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Experimental design
Once trained, animals were split into seven groups (Fig. 1).
All animals were administered saline (0.9%, s.c.) 30 min be-
fore 5-CSRTT testing for 4 days. Then, all animals were ad-
ministered PCP (2 mg/kg, s.c.) for 5 consecutive days. Using
the 4 days of saline treatment and the initial 2 days of PCP
treatment, the performance of the seven treatment groups was
balanced to minimize any difference in behavioral perfor-
mance (in the absence and presence of PCP) between groups
before aripiprazole or cariprazine were administered. Group-
matching was based on response accuracy, premature
responding, percent correct, percent omissions, correct
latency, and reward latency, as previously described (Amitai
et al. 2007). After group-matching, the animals were admin-
istered vehicle (2% Tween 80, p.o.), aripiprazole (1, 3, or
10 mg/kg, p.o.), or cariprazine (0.03, 0.1, or 0.3 mg/kg, p.o.)
60 min before 5-CSRTT testing. After 30 min, all animals
were administered PCP (2 mg/kg, s.c.), and 5-CSRTT testing
was initiated after a 30-min pre-treatment time.
Data analysis
The baseline performance, consisting of 4 days of saline treat-
ment, and the final 3 days of the PCP + cariprazine or
aripiprazole treatment were averaged. Data were analyzed by
Table 1 Description of the
behavioral measures assessed in
the 5-CSRTT
Measure Description
Accuracy Correct responses / (correct + incorrect) × 100
Percent correct Correct response / (correct + incorrect + omissions) × 100
Percent incorrect Incorrect response / (correct + incorrect + omissions) × 100
Percent omission Omitted responses / (correct + incorrect + omissions) × 100
Premature Response made during ITI prior to stimulus onset
Perseverative Initial inappropriate repeat response following a correct response
Timeout Subsequent inappropriate repeat responses made during the timeout period
Correct latency Time taken to make a correct response
Reward latency Time take to collect the food reward
Further information describing these measures can be found in Amitai and Markou (2010)
Fig. 1 Experimental study design. 5-CSRTT 5-choice serial reaction time test, PCP phencyclidine, PO oral gavage, SC subcutaneous
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two-way repeated measures ANOVA (day as repeated mea-
sures and treatment as the between-subject variable), followed
by a Fisher’s LSD post hoc test where appropriate. The a priori
hypothesis was that repeated PCP treatment would disrupt
incorrect responding, according to previous observations
(Amitai and Markou 2009; Amitai et al. 2007). Sample size
was selected based on prior experience from our lab with this
treatment regimen and behavioral procedure. As a result, no
formal power analysis was performed. Data were expressed as
means ± SEM, analyzed in Statsoft Statistica v8, and
displayed in GraphPad Prism v5.
Results
Percent incorrect responses, percent correct responses, accura-
cy, and percent omissions were evaluated in rats. Although the
day × treatment interaction for percent incorrect responding
failed to reach significance [F(3, 30) = 1.75, p = 0.18],
preplanned comparisons demonstrated that PCP alone signifi-
cantly increased incorrect responding compared to baseline
(p < 0.01; Fig. 2a, Table 2). This increase in incorrect
responding was not observed in cariprazine-treated (0.01–
0.3 mg/kg) animals (Fig. 2a, Table 2). Significant interactions
were evident for percent incorrect responses in the aripiprazole
treatment experiments [F(3, 32) = 3.32, p < 0.05]. PCP alone in-
creased the percentage of incorrect responses (p < 0.01), but
this effect was attenuated when aripiprazole (1 or 10 mg/kg)
was administered (Fig. 2b, Table 2). At 3 mg/kg, aripiprazole
was not effective in attenuating the PCP-induced increase in
incorrect responses (p < 0.01; Fig. 2b, Table 2).
For response accuracy, significant interactions were evident
with cariprazine [F(3, 30) = 3.81, p < 0.05] and aripiprazole [F(3,
32) = 5.51, p < 0.01]. Accuracy was significantly reduced by
PCP and 0.3 mg/kg cariprazine (p < 0.001; Table 2; Fig. 2c)
and by PCP and 10 mg/kg aripiprazole (p < 0.001; Fig. 2d), but
not by PCP alone. Similarly, the analysis of the percentage of
correct responses also resulted in significant interactions for
cariprazine [F(3, 30) = 13.68, p < 0.01] and aripiprazole [F(3,
32) = 9.99, p < 0.001]. As this measure was not reduced with
PCP alone, this effect was the result of fewer correct responses
made in animals that received PCP and cariprazine (0.1 and
0.3 mg/kg, p < 0.001 each) or PCP and aripiprazole (all three
doses, p < 0.05–p < 0.001) (Table 2).
For percent omissions, a significant interaction was evident
with both cariprazine [F(3, 30) = 14.67, p < 0.001] and
aripiprazole [F(3, 32) = 11.49, p < 0.001]. No increase was ob-
served in animals treated with PCP alone. Omissions were
increased in the groups that received PCP and cariprazine
(0.1 or 0.3 mg/kg; p < 0.001 each) or PCP and aripiprazole
(all three doses, p < 0.05 to p < 0.001) (Table 2).
In the 5-CSRTT, motoric impulsivity is reflected by the
number of premature responses before stimulus presentation,
although this measure could also reflect timing capabilities
(Cope et al. 2016). Premature responding was significantly
disrupted with cariprazine [F(3, 30) = 6.04, p < 0.01] and
aripiprazole [F(3, 32) = 3.06, p < 0.05]. Compared to baseline,
premature responding was significantly increased in PCP-
treated animals (p < 0.05; Fig. 3a, Table 2). No significant
difference from baseline was evident in two cariprazine
treatment groups (0.03, 0.1 mg/kg). The highest dose of
cariprazine (0.3 mg/kg) significantly reduced premature
responding compared to baseline performance (p < 0.01;
Fig. 3a, Table 2). In the aripiprazole experiments, premature
responses approached a significant increase in PCP-treated
animals (p = 0.06) and were decreased in animals treated
with PCP and 1 mg/kg aripiprazole (p < 0.05; Fig. 3b,
Table 2). However, this effect likely reflected the unusually
high baseline level of premature responses rather than a
reduction per se. Balancing the high level of baseline pre-
mature responding in the PCP and 1 mg/kg aripiprazole
group (by removing two animals from this group) with that
of all other groups at baseline diminished the interaction,
and the effect just failed to reach statistical significance
[F(3, 30) = 2.78, p = 0.058]. Aripiprazole attenuated the
PCP-induced increase in premature responding at all doses
tested (Fig. 3b, Table 2).
A surrogate measure for cognitive flexibility in the 5-
CSRTT is the number of perseverative responses and timeout
responses. Cariprazine significantly influenced perseverative
responding [F(3, 30) = 6.02, p < 0.001]. However, this effect
was not driven by a PCP-induced increase. Rather, persever-
ative responding was significantly reduced after cariprazine
treatment (0.3 mg/kg, p < 0.001; Table 2). No effect on per-
severative responding was observed with aripiprazole [F(3,
32) = 0.55, ns]. The number of timeout responses was signifi-
cantly influenced by both cariprazine [F(3, 30) = 4.30, p < 0.05]
and aripiprazole [F(3, 32) = 3.37, p < 0.05]. Timeout
responding was significantly increased in the PCP-treated
group compared to baseline (p < 0.01); no significant changes
from baseline were observed with any cariprazine dose
(Fig. 4a, Table 2). In contrast, the PCP-induced increase in
timeout responding (p < 0.01) was attenuated in animals re-
ceiving 1 and 10 mg/kg aripiprazole (Fig. 4b, Table 2). A
significant increase in timeout responding was evident in an-
imals receiving PCP and 3 mg/kg aripiprazole (p < 0.05; Fig.
4b, Table 2).
When the number of completed trials was analyzed, signif-
icant interactions were evident with cariprazine [F(3, 30) =
11.59, p < 0.001] and aripiprazole [F(3, 32) = 7.37, p < 0.001].
PCP alone had no effect on trials completed; therefore, the
significant interactions were attributable to the significant re-
duction of the number of trials completed within a session
with PCP and cariprazine (0.1 mg/kg, p < 0.01; 0.3 mg/kg,
p < 0.001) or with PCP and aripiprazole (10 mg/kg,
p < 0.001) (Table 2).
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In the 5-CSRTT, a surrogate measure for processing speed
can be evaluated by comparing correct latency (latency to
correct response) and reward latency (time to reward retriev-
al). In the cariprazine treatment experiments, no interaction
was observed for correct latency [F(3, 30) = 2.19, p = 0.1], but
a main effect of Day was present [F(1, 30) = 24.69, p < 0.001].
ANOVA did not reveal any effect on reward latency [F(3, 30) =
1.01, NS]. Hence, cariprazine treatment slowed processing
speed without affecting overall motoric capability. For
aripiprazole, a main effect of Day was also evident when cor-
rect latency was analyzed [F(1, 32) = 12.27, p < 0.01], indicat-
ing that the latency to make a correct response was elevated in
all groups. No significant effect was observed for reward la-
tency, although a main effect of Day approached significance
[F(1, 32) = 3.66, p < 0.1] (Table 2).
Discussion
The 5-CSRTT assesses a range of cognitive domains, includ-
ing aspects of sustained attention, motoric impulsivity, speed
of processing, and cognitive flexibility. In this study, we have
shown that a repeated PCP treatment regimen disrupted sev-
eral of these domains in rats in ways that are similar to those
observed in patients with schizophrenia. Namely, PCP treat-
ment significantly increased the number of incorrect, prema-
ture, and timeout responses, which can be considered proxy
measurements of attention deficits, motoric impulsivity, and
cognitive inflexibility, respectively, symptoms that are fre-
quently observed in patients with schizophrenia (Amitai and
Markou 2010). Moreover, these effects occurred without af-
fecting measures such as completed trials or reward latency,
Fig. 2 Effects of cariprazine and aripiprazole on PCP-induced alterations
in attentional processing: incorrect responses (a, b) and response accuracy
(c, d). Measures are shown as means ± SEM; p values are based on
ANOVA planned comparisons (cariprazine; incorrect responses) or post
hoc Fisher least significant difference tests (cariprazine; response
accuracy, and aripiprazole). **p < 0.01 compared to baseline. ARI
aripiprazole, CAR cariprazine, PCP phencyclidine, Veh vehicle
1408 Psychopharmacology (2018) 235:1403–1414
suggesting PCP-induced deficits were not the result of non-
specific performance alterations. In addition, all three
cariprazine doses significantly diminished the PCP-induced
increases in incorrect, premature, and timeout responses.
However, the two higher cariprazine doses also significantly
reduced the number of trials completed, percent accuracy, and
number of correct responses, suggesting that these doses re-
sulted in a non-specific suppression of responses. This non-
Table 2 5-CSRTT performance
Measure PCP + Veh PCP + cariprazine PCP + aripiprazole
0.03 mg/kg 0.1 mg/kg 0.3 mg/kg 1 mg/kg 3 mg/kg 10 mg/kg
Incorrect responses (%) Baseline 4.3 (0.8) 4.9 (0.8) 4.9 (0.7) 5.0 (1.2) 5.8 (1.1) 5.6 (0.8) 4.0 (1.2)
Treatment 7.1 (0.9)* 5.4 (0.7) 5.7 (1.4) 5.5 (1.5) 6.0 (1.1) 8.2 (1.2)* 4.1 (1.2)
Correct reponses (%) Baseline 78.4 (3.0) 79.2 (3.3) 75.6 (2.1) 79.2 (3.3) 79.4 (2.5) 79.2 (2.3) 80.3 (3.2)
Treatment 71.4 (3.0) 76.6 (3.4) 51.6 (2.6)* 36.4 (6.0)* 65.2 (4.9)* 66.9 (3.0)* 38.7 (5.2)*
Accuracy (%) Baseline 94.7 (1.1) 94.1 (1.0) 94.0 (0.9) 93.9 (1.6) 93.4 (1.3) 93.2 (1.1) 95.0 (1.7)
Treatment 90.8 (1.3) 93.1 (1.0) 90.1 (2.4) 80.3 (4.9)* 91.0 (1.3) 88.6 (1.7) 73.0 (7.5)*
Omissions (%) Baseline 17.3(2.6) 16.0 (3.1) 19.5 (2.0) 15.7 (2.9) 15.0 (2.3) 15.2 (1.7) 15.8 (2.4)
Treatment 21.5 (2.1) 18.0 (3.1) 42.6 (2.8)* 58.2 (6.8)* 28.8 (5.1)* 24.9 (2.5)* 57.2 (5.7)*
Trials completed, n Baseline 99.1 (0.6) 99.1 (0.6) 98.9 (0.7) 96.6 (2.5) 99.0 (0.5) 99.4 (0.4) 99.1 (0.9)
Treatment 89.1 (5.6) 97.7 (1.0) 79.2 (5.9)* 49.1 (9.8)* 86.6 (6.3) 94.6 (2.5) 56.1 (9.6)*
Premature responses, n Baseline 6.7 (1.4) 10.3 (1.1) 8.3 (1.7) 9.7 (2.6) 11.0 (3.1) 9.3 (1.7) 6.8 (1.2)
Treatment 12.8 (3.3)* 10.1 (1.8) 3.9 (1.4) 2.5 (1.2)* 9.4 (2.4) 8.2 (2.4) 2.7 (0.9)
Timeout responses, n Baseline 6.8 (1.1) 7.5 (1.4) 5.3 (1.0) 7.8 (1.6) 7.0 (2.3) 8.8 (1.6) 6.2 (1.3)
Treatment 12.9 (3.2)* 9.4 (1.3) 4.6 (1.6) 4.3 (1.5) 6.6 (1.3) 14.0 (2.7)* 5.0 (1.6)
Correct latency (s) Baseline 0.8 (0.0) 0.8 (0.0) 0.8 (0.0) 0.8 (0.0) 0.8 (0.0) 0.9 (0.0) 0.8 (0.0)
Treatment 0.8 (0.0) 0.8 (0.0) 1.0 (0.0) 1.0 (0.1) 0.9 (0.1) 0.9 (0.0) 0.9 (0.1)
Reward latency (s) Baseline 1.8 (0.1) 1.7 (0.2) 2.1 (0.2) 2.1 (0.3) 1.8 (0.1) 2.0 (0.2) 1.7 (0.2)
Treatment 1.6 (0.2) 1.5 (0.1) 2.5 (0.3) 1.8 (0.3) 1.7 (0.1) 2.0 (0.2) 1.5 (0.2)
Perseverative responses, n Baseline 6.5 (1.0) 5.8 (1.2) 6.8 (1.4) 9.8 (1.8) 7.2 (0.7) 8.7 (2.1) 7.0 (0.8)
Treatment 7.3 (1.9) 7.2 (0.8) 5.6 (1.2) 2.8 (1.2)* 8.1 (2.3) 8.0 (1.2) 4.7 (1.6)
Measures are shown as mean ± SEM
5-CSRTT 5-choice serial reaction time task, PCP phencyclidine, Veh vehicle
*p < 0.05
Fig. 3 Effects of cariprazine (a) and aripiprazole (b) on PCP-induced
impulsivity: premature responses. Measures are shown as mean ± SEM.
p values are based on post hoc Fisher least significant difference test
(cariprazine) or ANOVA planned comparison tests (aripiprazole).
*p < 0.05; **p < 0.01 compared to baseline. ARI aripiprazole, CAR
cariprazine, PCP phencyclidine, Veh vehicle. aTwo outliers were
removed from the PCP + 1 mg/kg aripiprazole group
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specific response suppression appears to be a characteristic of
antipsychotic drugs, as similar non-specific effects due to high
doses of antipsychotic compounds were also reported in an
earlier study (Amitai et al. 2007). Importantly, the lowest
cariprazine dose (0.03 mg/kg) improved the 5-CSRTT perfor-
mance without inducing these non-specific disruptions, sug-
gesting that this dose is effective in attenuating PCP-induced
impairments in cognition. Of note, this cariprazine dose is
lower than the antipsychotic-like effective dose (ED50 =
0.09 mg/kg) that attenuated PCP-induced increases in loco-
motor activity in a previous study (Gyertyán et al. 2011). It
should be noted, however, that some effects presented here
were marginal and only statistically significant when a priori
pre-planned comparisons were applied. Nonetheless, the find-
ings of the present study provide support for the hypothesis
that low doses of cariprazine may be effective against cogni-
tive symptoms of schizophrenia.
Aripiprazole treatment resulted in a slightly different atten-
tion response profile. Two aripiprazole doses (1 and 10 mg/kg)
significantly reversed the PCP-induced increases in incorrect
and timeout responses. However, all three aripiprazole doses
also decreased the percentage of correct responses and increased
the number of omissions, suggesting that aripiprazole may di-
rectly impair select forms of attention, resulting in a reduction in
stimulus detection.While there was an apparent dose-dependent
reduction in premature response in aripiprazole-treated animals,
the interaction for this measure did not reach statistical signifi-
cance.While it may be possible that aripiprazole improves PCP-
induced increases in motoric impulsivity, further experiments
and replication are required before firm conclusions can be
made. The effects of drug treatment on 5-CSRTT performance
were not evaluated in the absence of PCP; therefore, it is unclear
to what extent any or all of these effects of aripiprazole are due
to its action on PCP-induced responses vs its direct effects
on 5-CSRTT performance, or an interaction between the
two. These findings are similar to those of an earlier study,
which used the competitive NMDA receptor antagonist
CPP to induce cognitive deficits in rats that underwent the
5-CSRTT (Carli et al. 2011). Aripiprazole (1 and 3 mg/kg)
ameliorated CPP-induced decreases in accuracy and increases
in perseverative overresponding, suggesting that aripiprazole
can affect both the attention and the cognitive flexibility do-
mains of cognition at these doses. Furthermore, these data
support the doses chosen for the present study, although lower
doses could be tested in the future.
Our findings are consistent with those reported in previous
studies in which second-generation antipsychotics attenuated
PCP- or CPP-induced cognitive deficits in the 5-CSRTT
(Amitai et al. 2007; Carli et al. 2011). Clozapine reversed
chronic PCP-induced decreases in accuracy and increases in
premature responses in the 5-CSRTT, but had no effect on
measures of cognitive flexibility (Amitai et al. 2007). In a later
study, quetiapine failed to modulate any PCP-induced cogni-
tive deficits modeled by the 5-CSRTT (Amitai and Markou
2009). Olanzapine (0.3 and 1.0 mg/kg) reduced CPP-induced
attention deficits and premature responding, but did not affect
perseverative responses (Carli et al. 2011). Taken together,
these studies indicate that different antipsychotics can specif-
ically modulate discrete cognitive domains. Clinical studies
have also shown that different antipsychotics are effective
against different aspects of cognition in patients with schizo-
phrenia (Meltzer and McGurk 1999; Sharma and Mockler
1998; Strous et al. 2006; Velligan et al. 2002). At the dose that
specifically attenuated PCP-induced cognitive deficits,
cariprazine exerted broad effects on multiple cognitive do-
mains, suggesting that cariprazine may be of use in patients
with schizophrenia who exhibit a range of cognitive
symptoms.
Fig. 4 Effects of cariprazine (a) and aripiprazole (b) on PCP-induced
cognitive flexibility: timeout responses. Measures are shown as means
± SEM. p values are based on post hoc Fisher least significant difference
test. *p < 0.05; **p < 0.01 compared to baseline. ARI aripiprazole, CAR
cariprazine, PCP phencyclidine, Veh vehicle
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The diverse effects of different antipsychotic compounds
could be related to their varied receptor pharmacology pro-
files. Clozapine, quetiapine, and olanzapine are dopamine D2
receptor and serotonin 5-HT2A receptor antagonists (Bymaster
et al. 1996; Ellenbroek and Cesura 2015; Moore et al. 1992;
Schmidt et al. 2001). In contrast, cariprazine and aripiprazole
are partial agonists at dopamine D2 and D3 receptors and se-
rotonin 5-HT1A receptors and antagonists at 5-HT2A receptors
(Kiss et al. 2010). Importantly, alterations in glutamate trans-
mission can impact dopamine levels, as NMDA receptor an-
tagonism results in aberrant dopamine transmission (Adams
et al. 2002; Kapur and Seeman 2002; Pouvreau et al. 2016).
Moreover, NMDA antagonism induces upregulation of
striatal dopamine D2 receptors (Nair et al. 1998). Striatal do-
pamine D2 receptor overexpression produces motivational
and cognitive impairment associated with schizophrenia
(Kellendonk et al. 2006; Simpson et al. 2011) and alterations
in the PFC inhibitory transmission (Li et al. 2011) reminiscent
to those observed after the PCP treatment. Increased expres-
sion of striatal dopamine D2 receptors may, therefore, contrib-
ute to the disruptive effects of NMDA antagonists on atten-
tional processes and provide a potential mechanism for the
behavioral attenuation when compounds that modulate the
activity of dopamine D2-like receptors are administered.
While dopamine D2 receptors are expressed throughout the
brain, high dopamine D3 receptor expression occurs in several
particular regions of the brain, including the prefrontal cortex,
nucleus accumbens, and ventral tegmental area, that are asso-
ciated with negative, cognitive, and mood symptoms of
schizophrenia (Gross and Drescher 2012). Because the com-
pounds in this study were administered systemically, it is not
possible to pinpoint the exact region of the brain in which they
function to modulate cognitive impairment. However, an im-
paired cognition associated with schizophrenia is thought to
be associated with hypofunction of the prefrontal cortex, in-
cluding reduced dopaminergic activity (Goldman-Rakic et al.
2004; Slifstein et al. 2015).
The fact that cariprazine acts as a partial agonist at D3 and
D2 receptors may have important implications for its therapeu-
tic profile that makes its use preferable to that of pure D3/D2
receptor antagonists. It has been hypothesized that a general
dysregulation of dopaminergic systems in patients with
schizophrenia can result in both hyperactivity in circuits asso-
ciated with positive symptoms and hypoactivity in those asso-
ciated with cognitive and negative symptoms (Maia and Frank
2017). Partial agonists, by definition, have the ability to con-
strain activity in neurotransmitter-receptor circuits within a
certain range, potentially allowing for the normalization of
both hyperactive and hypoactive circuits. Therefore, the par-
tial agonist properties of cariprazine may allow for the simul-
taneous treatment of the multiple symptom domains of schizo-
phrenia, acting as an antagonist to reduce dopaminergic hy-
peractivity associated with positive symptoms and as an
agonist to increase dopaminergic activity in brain regions as-
sociated with negative and cognitive symptoms.
Based on the preferential distribution of D3 receptors in
corticolimbic circuits (Sokoloff et al. 1990), it has been sug-
gested that dopamine antagonists displaying high affinity for
both D3 and D2 receptors may yield a favorable antipsychotic
therapeutic profile in terms of maximizing efficacy (Gyertyán
et al. 2008; Kiss et al. 2008). Cariprazine exhibits such a
binding profile, having a higher affinity and selectivity for
the D3 vs the D2 receptor. In contrast, aripiprazole has a higher
affinity and selectivity for the D2 vs the D3 receptor, as mea-
sured in various in vitro assays (de Bartolomeis et al. 2015;
Kiss et al. 2010). Moreover, in the in vivo rodent studies,
cariprazine but not aripiprazole showed high occupancy of
both D2 and D3 receptors at antipsychotic-like effective doses
(Gyertyán et al. 2011), indicating that potentially, cariprazine
would have a greater impact on D3 receptor activity than
aripiprazole. Interestingly, while the low and high doses of
aripiprazole attenuated PCP-induced impairments in incorrect
responding, the medium dose was not effective. Dopamine
transmission-mediated modulation of cognitive processing is
extremely sensitive to an optimal range of activity (Floresco
2013). While further investigations are necessary to elucidate
the precise mechanism underlying this unusual effect, it may
reflect aripiprazole displaying optimal or sub-optimal effects
on dopamine transmission depending on the dose adminis-
tered. The absence of this usual effect in cariprazine treated
rats may also reflect differences in D2 and D3 receptor selec-
tivity, but the precise mechanism for this dissociation is un-
known and requires further investigation. Cariprazine was
previously shown to reverse behavioral, cognitive, and social
deficits in PCP-induced animal models of schizophrenia
(Gyertyán et al. 2011; Neill et al. 2016; Watson et al. 2016;
Zimnisky et al. 2013). These effects are likely due to
cariprazine’s partial agonist activity on the D3 receptor, as
cariprazine significantly ameliorated cognitive deficits in-
duced by acute administration of PCP in wild-type mice, but
not in D3 receptor knockout mice (Zimnisky et al. 2013). The
more specific effect of cariprazine compared with aripiprazole
on impaired cognition induced by PCP in this study may
therefore be due to its preferential activity at the D3 receptor.
Future studies using dopamine D3 receptor knockout mice in
the 5-CSRTTare necessary to determine whether the effects of
cariprazine are specific to the D3 receptor.
In summary, cariprazine exhibited a better overall cog-
nitive profile than aripiprazole in the attenuation of PCP-
induced deficits in the 5-CSRTT performance. Although
higher tested doses of both compounds appeared to induce
non-specific effects, the lowest dose of cariprazine signif-
icantly reversed the inappropriate responses induced by
PCP and may therefore have potential for improving at-
tentional impairment and other cognitive defects associat-
ed with schizophrenia.
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